BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arroyo V, Angeli P, Moreau R, Jalan R, Clària J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M; investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif). The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol 2021;74:670-85. [PMID: 33301825 DOI: 10.1016/j.jhep.2020.11.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Li H, Xia J, Wang X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Liu J, Deng G, Zheng Y, Yan H, Qiao L, Xiang X, Zhang Q, Chen R, Chen J, Luo S, Gao, Ji L, Li J, Zhou X, Ren H, Lu S, Li S, Zhang W, Zheng X. Baseline Neutrophil-to-Lymphocyte Ratio Is Independently Associated With 90-Day Transplant-Free Mortality in Patients With Cirrhosis. Front Med (Lausanne) 2021;8:726950. [PMID: 34532334 DOI: 10.3389/fmed.2021.726950] [Reference Citation Analysis]
2 Gambino C, Piano S. Identifying the four shades of acute decompensation of cirrhosis. United European Gastroenterol J 2021;9:421-2. [PMID: 33939291 DOI: 10.1002/ueg2.12074] [Reference Citation Analysis]
3 Hassan HM, Cai Q, Liang X, Xin J, Ren K, Jiang J, Shi D, Lu Y, Li T, Shang Y, He L, Chen X, Sun S, Li P, Guo B, Chen J, Yang H, Hu W, Chen X, Li J. Transcriptomics reveals immune-metabolism disorder in acute-on-chronic liver failure in rats. Life Sci Alliance 2022;5:e202101189. [PMID: 34853163 DOI: 10.26508/lsa.202101189] [Reference Citation Analysis]
4 Li J, Guo C, Wu J. The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis. Drug Des Devel Ther 2021;15:2619-28. [PMID: 34168433 DOI: 10.2147/DDDT.S310163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lisman T, Luyendyk JP. Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome. J Hepatol 2021;74:1264-5. [PMID: 33347950 DOI: 10.1016/j.jhep.2020.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Queck A, Uschner FE, Ferstl PG, Schulz M, Brol MJ, Praktiknjo M, Schierwagen R, Klein S, Strassburg CP, Meyer C, Jansen C, Berres ML, Trebicka J. Role of circulating angiogenin levels in portal hypertension and TIPS. PLoS One 2021;16:e0256473. [PMID: 34432848 DOI: 10.1371/journal.pone.0256473] [Reference Citation Analysis]
7 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
8 Wong YJ, Kumar R, Chua YJJ, Ang TL. Long-term albumin infusion in decompensated cirrhosis: A review of current literature . World J Hepatol 2021; 13(4): 421-432 [PMID: 33959225 DOI: 10.4254/wjh.v13.i4.421] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Samuel D. Systemic inflammation and liver cirrhosis complications: Driving or secondary event? How to square the circle? J Hepatol 2021;74:508-10. [PMID: 33478857 DOI: 10.1016/j.jhep.2021.01.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Claeys W, Van Hoecke L, Lefere S, Geerts A, Verhelst X, Van Vlierberghe H, Degroote H, Devisscher L, Vandenbroucke RE, Van Steenkiste C. The neurogliovascular unit in hepatic encephalopathy. JHEP Rep 2021;3:100352. [PMID: 34611619 DOI: 10.1016/j.jhepr.2021.100352] [Reference Citation Analysis]
11 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ginès P. Robert W Schrier, an influential observer from outside Hepatology (1936-2021). J Hepatol 2021:S0168-8278(21)00180-X. [PMID: 33892988 DOI: 10.1016/j.jhep.2021.03.008] [Reference Citation Analysis]
13 Scheiner B, Balcar L, Johanna Nussbaumer R, Weinzierl J, Paternostro R, Simbrunner B, Hartl L, Jachs M, Bauer D, Stättermayer AF, Semmler G, Pinter M, Ay C, Quehenberger P, Trauner M, Reiberger T, Lisman T, Mandorfer M. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2021.12.038] [Reference Citation Analysis]
14 Zhu X, Hou Y, Ye X, Zou Y, Xia X, Yang S, Huang P, Yu R. Identifying and Exploring the Candidate Susceptibility Genes of Cirrhosis Using the Multi-Tissue Transcriptome-Wide Association Study. Front Genet 2022;13:878607. [DOI: 10.3389/fgene.2022.878607] [Reference Citation Analysis]
15 García-Peñarrubia P, Ruiz-Alcaraz AJ, Ruiz-Ballester M, Ramírez-Pávez TN, Martínez-Esparza M. Recent insights into the characteristics and role of peritoneal macrophages from ascites of cirrhotic patients. World J Gastroenterol 2021; 27(41): 7014-7024 [PMID: 34887625 DOI: 10.3748/wjg.v27.i41.7014] [Reference Citation Analysis]
16 Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol 2021;12:718783. [PMID: 34393832 DOI: 10.3389/fphys.2021.718783] [Reference Citation Analysis]
17 Gupta T, Ranga N, Goyal SK. Predictors of mortality at 28-days in infection associated acute kidney injury in cirrhosis. World J Hepatol 2022; 14(3): 592-601 [DOI: 10.4254/wjh.v14.i3.592] [Reference Citation Analysis]
18 Sekandarzad A, Weber E, Prager EP, Graf E, Bettinger D, Wengenmayer T, Supady A. Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)-a single center, open-label, three-arm, randomized, controlled intervention trial. Trials 2022;23:222. [PMID: 35303938 DOI: 10.1186/s13063-022-06139-6] [Reference Citation Analysis]
19 Schulz MS, Gu W, Schnitzbauer AA, Trebicka J. Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure. Transpl Int 2022;35:10108. [DOI: 10.3389/ti.2022.10108] [Reference Citation Analysis]
20 Khanam A, Kottilil S. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. Front Med (Lausanne) 2021;8:752875. [PMID: 34820395 DOI: 10.3389/fmed.2021.752875] [Reference Citation Analysis]
21 Russo FP, Piano S, Bruno R, Burra P, Puoti M, Masarone M, Montagnese S, Ponziani FR, Petta S, Aghemo A; Italian Association for the Study of the Liver. Italian association for the study of the liver position statement on SARS-CoV2 vaccination. Dig Liver Dis 2021;53:677-81. [PMID: 33941488 DOI: 10.1016/j.dld.2021.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chen YY, Li H, Xu BY, Zheng X, Li BL, Wang XB, Huang Y, Gao YH, Qian ZP, Liu F, Lu XB, Shang J, Li H, Wang SY, Zhang YH, Meng ZJ; Chinese Chronic Liver Failure (CLIF) Consortium. Plasma Exchange-Based Non-bioartificial Liver Support System Improves the Short-Term Outcomes of Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure: A Multicenter Prospective Cohort Study. Front Med (Lausanne) 2021;8:779744. [PMID: 34869500 DOI: 10.3389/fmed.2021.779744] [Reference Citation Analysis]
23 Schulz M, Diehl V, Trebicka J, Wygrecka M, Schaefer L. Biglycan: A regulator of hepatorenal inflammation and autophagy. Matrix Biology 2021;100-101:150-61. [DOI: 10.1016/j.matbio.2021.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yu J, Shi X, Ma J, Chen R, Dong S, Lu S, Wu J, Yan C, Wu J, Zheng S, Li L, Xu X, Cao H. C-Reactive Protein Is an Independent Predictor of 30-Day Bacterial Infection Post-Liver Transplantation. Biomolecules 2021;11:1195. [PMID: 34439862 DOI: 10.3390/biom11081195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Román E, Poca M, Amorós-Figueras G, Rosell-Ferrer J, Gely C, Nieto JC, Vidal S, Urgell E, Ferrero-Gregori A, Alvarado-Tapias E, Cuyàs B, Hernández E, Santesmases R, Guarner C, Escorsell À, Soriano G. Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis. Sci Rep 2021;11:20415. [PMID: 34650096 DOI: 10.1038/s41598-021-99199-8] [Reference Citation Analysis]
26 Bucsics T, Lampichler K, Vierziger C, Schoder M, Wolf F, Bauer D, Simbrunner B, Hartl L, Jachs M, Scheiner B, Trauner M, Gruenberger T, Karnel F, Mandorfer M, Reiberger T. Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. Dig Dis Sci 2022. [PMID: 35301618 DOI: 10.1007/s10620-022-07443-6] [Reference Citation Analysis]
27 Li M, Li K, Tang S, Lv Y, Wang Q, Wang Z, Luo B, Niu J, Zhu Y, Guo W, Bai W, Wang E, Xia D, Wang Z, Li X, Yuan J, Yin Z, Trebicka J, Han G. Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100448] [Reference Citation Analysis]
28 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem 2021;:114388. [PMID: 34587512 DOI: 10.1016/j.ab.2021.114388] [Reference Citation Analysis]
30 Schmid S, Schlosser S, Gülow K, Pavel V, Müller M, Kratzer A. Interprofessional Collaboration between ICU Physicians, Staff Nurses, and Hospital Pharmacists Optimizes Antimicrobial Treatment and Improves Quality of Care and Economic Outcome. Antibiotics 2022;11:381. [DOI: 10.3390/antibiotics11030381] [Reference Citation Analysis]
31 Arroyo V, Fernández J, Moreau R. Reply to: "Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome". J Hepatol 2021;74:1265-7. [PMID: 33640401 DOI: 10.1016/j.jhep.2021.02.021] [Reference Citation Analysis]
32 Brennan PN, MacMillan M, Manship T, Moroni F, Glover A, Graham C, Semple S, Morris DM, Fraser AR, Pass C, McGowan NWA, Turner ML, Lachlan N, Dillon JF, Campbell JDM, Fallowfield JA, Forbes SJ. Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH). BMJ Open 2021;11:e053190. [PMID: 34750149 DOI: 10.1136/bmjopen-2021-053190] [Reference Citation Analysis]
33 Csak T. Hepatorenal Syndrome. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.013] [Reference Citation Analysis]
34 Kerbert AJC, Gupta S, Alabsawy E, Dobler I, Lønsmann I, Hall A, Nielsen SH, Nielsen MJ, Gronbaek H, Amoros À, Yeung D, Macnaughtan J, Mookerjee RP, Macdonald S, Andreola F, Moreau R, Arroyo V, Angeli P, Leeming DJ, Treem W, Karsdal MA, Jalan R. Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure. JHEP Rep 2021;3:100355. [PMID: 34805815 DOI: 10.1016/j.jhepr.2021.100355] [Reference Citation Analysis]
35 Michel M, Hess C, Kaps L, Kremer WM, Hilscher M, Galle PR, Moehler M, Schattenberg JM, Wörns MA, Labenz C, Nagel M. Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. Sci Rep 2021;11:20506. [PMID: 34654829 DOI: 10.1038/s41598-021-00119-7] [Reference Citation Analysis]
36 Singanayagam A, Triantafyllou E. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. Front Immunol 2021;12:661182. [PMID: 33868313 DOI: 10.3389/fimmu.2021.661182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Xiu AY, Ding Q, Li Z, Zhang CQ. Doxazosin Attenuates Liver Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via Activation of the PI3K/Akt/mTOR Signaling Pathway. Drug Des Devel Ther 2021;15:3643-59. [PMID: 34456560 DOI: 10.2147/DDDT.S317701] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Maiwall R, Sarin SK. Plasma Exchange in Acute and Acute on Chronic Liver Failure. Semin Liver Dis 2021. [PMID: 34261138 DOI: 10.1055/s-0041-1730971] [Reference Citation Analysis]
39 Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34703031 DOI: 10.1038/s41575-021-00520-7] [Reference Citation Analysis]
40 Kostallari E, Valainathan S, Biquard L, Shah VH, Rautou PE. Role of extracellular vesicles in liver diseases and their therapeutic potential. Adv Drug Deliv Rev 2021;175:113816. [PMID: 34087329 DOI: 10.1016/j.addr.2021.05.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Langer MM, Eickelmann C, Kleinbongard P, Lange CM. Impaired mitochondrial complex IV respiration in peripheral blood mononuclear cells discriminates acute-on-chronic liver failure from acute decompensation. J Hepatol 2022:S0168-8278(22)00277-X. [PMID: 35562066 DOI: 10.1016/j.jhep.2022.04.037] [Reference Citation Analysis]
42 Basho K, Bettinger D, Boettler T. Reply to: "IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?". J Hepatol 2021;75:231-2. [PMID: 33771608 DOI: 10.1016/j.jhep.2021.03.015] [Reference Citation Analysis]
43 Gambino C, Piano S, Angeli P. Acute-on-Chronic Liver Failure in Cirrhosis. J Clin Med 2021;10:4406. [PMID: 34640424 DOI: 10.3390/jcm10194406] [Reference Citation Analysis]
44 Lamatsch S, Sittner R, Tacke F, Engelmann C. Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opin Drug Discov 2021;:1-10. [PMID: 34971342 DOI: 10.1080/17460441.2022.2020755] [Reference Citation Analysis]
45 Driever EG, Lisman T. Effects of Inflammation on Hemostasis in Acutely Ill Patients with Liver Disease. Semin Thromb Hemost 2022. [PMID: 35135033 DOI: 10.1055/s-0042-1742438] [Reference Citation Analysis]